Zacks Investment Research
29 Jun 2026, 11:51 UTC · 2h ago
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
29 Jun 2026, 11:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Myriad Genetics (MYGN) expanded the availability of its Precise MRD assay to include patients with breast, colorectal, and renal cancers. — Expansion of a high-tech diagnostic tool into more cancer types increases the addressable market and revenue potential for the company.
+0.50Myriad Genetics is expected to report a quarterly loss of $0.03 per share and a 3.7% year-over-year decrease in revenue. — Projected declines in revenue and continued losses represent fundamental headwinds despite short-term price action.
-0.30The consensus EPS estimate for Myriad Genetics has remained unchanged over the last 30 days. — The lack of upward earnings revisions suggests a lack of fundamental catalyst to sustain the recent price rally.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Shares rallied 8.3% due to optimism surrounding the expanded availability of Precise MRD and holds a Zacks Rank #2 (Buy).
Shares closed 3.7% lower in the last trading session.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
14h ago
